Indications for liver transplantation in adults: Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX)

Wiener Klinische Wochenschrift

Volumn 128, Issue 19-20, 2016, Pages 679-690

  Graziadei, Ivo ^a,b   Zoller, Heinz ^b   Fickert, Peter ^c   Schneeberger, Stefan ^b   Finkenstedt, Armin ^b   Peck Radosavljevic, Markus ^a   Müller, Helmut ^c   Kohl, Claudia ^b   Sperner Unterweger, Barbara ^b   Eschertzhuber, Stephan ^b   Hofer, Harald ^a   Öfner, Dietmar ^b   Tilg, Herbert ^b   Vogel, Wolfgang ^b   Trauner, Michael ^a   Berlakovich, Gabriela ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Acute liver failure; Cholangiocellular carcinoma; Chronic hepatitis; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

ACUTE LIVER FAILURE; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; BARIATRIC SURGERY; BILE DUCT CARCINOMA; CHOLANGITIS; CLINICAL EVALUATION; EVIDENCE BASED PRACTICE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHERITED METABOLIC LIVER DISEASE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY (TOPIC); NONALCOHOLIC FATTY LIVER; PRIMARY BILIARY CHOLANGITIS; PRIMARY SCLEROSING CHOLANGITIS; RARE DISEASE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; AUSTRIA; GASTROENTEROLOGY; HEALTH CARE ORGANIZATION; PATIENT SELECTION; PRACTICE GUIDELINE; STANDARDS; TRANSPLANTATION;

AUSTRIA; GASTROENTEROLOGY; HEALTH CARE RATIONING; HUMANS; LIVER TRANSPLANTATION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; TISSUE AND ORGAN HARVESTING; TISSUE AND ORGAN PROCUREMENT;

EID: 84984920917     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-016-1046-1     Document Type: Article

References (68)

1. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66:726–35.
2. Keeffe EB. Patient selection and listing policies for liver transplantation. J Gastroenterol Hepatol. 1999;14(Suppl):S42–7.
3. Freeman RB. MELD: the holy grail of organ allocation? J Hepatol. 2005;42:16–20.
4. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.
5. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Borg PC ter. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–71.
6. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–70.
7. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7:567–80.
8. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91–6.
9. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant. 2005;5:307–13.
10. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, Burroughs AK. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl. 2006;12:1049–61.
11. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011;54:1297–306.
12. Wedd J, Bambha KM, Stotts M, Laskey H, Colmenero J, Gralla J, Biggins SW. Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation. Liver Transpl. 2014;20:1193–201.
13. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2014;370:1170–1.
14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.
15. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
16. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.
17. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008;8:2547–57.
18. Finkenstedt A, Vikoler A, Portenkirchner M, Mulleder K, Maglione M, Margreiter C, Moser P, et al. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int. 2015; doi:10.1111/liv.12966.
19. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014;20:937–44.
20. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, Hoppe-Lotichius M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260–7.
21. Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2007;13:272–9.
22. Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl. 2013;19:1108–18.
23. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.
24. Sapisochin G, Lope CR de, Gastaca M, Urbina JO de, Lopez-Andujar R, Palacios F, Ramos E, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg. 2014;259:944–52.
25. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88–98, e83; quiz e14.
26. Robles R, Figueras J, Turrion VS, Margarit C, Moya A, Varo E, Calleja J, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg. 2004;239:265–71.
27. Hong JC, Petrowsky H, Kaldas FM, Farmer DG, Durazo FA, Finn RS, Saab S, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg. 2011;212:514–20, discussion 520–511.
28. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:S14–8.
29. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl. 2003;9:S44–7.
30. Rubin A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011;35:805–12.
31. Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, Mikuz G, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 2012;18:671–9.
32. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192–204.
33. Everson GT, Terrault NA, Lok AS, Rodrigo R del, Brown RS Jr., Saab S, Shiffman ML, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–62.
34. Charlton M, Gane E, Manns MP, Brown RS Jr., Curry MP, Kwo PY, Fontana RJ, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–17.
35. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr., Gordon F, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–82.
36. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.
37. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26.
38. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–62.
39. Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011;17:751–9.
40. DiMartini A, Crone C, Dew MA. Alcohol and substance use in liver transplant patients. Clin Liver Dis. 2011;15:727–51.
41. DiMartini A, Dew MA, Day N, Fitzgerald MG, Jones BL, deVera ME, Fontes P. Trajectories of alcohol consumption following liver transplantation. Am J Transplant. 2010;10:2305–12.
42. Rice JP, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013;19:1377–86.
43. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–800.
44. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl. 2012;18:1277–89.
45. Finkenstedt A, Graziadei IW, Oberaigner W, Hilbe W, Nachbaur K, Mark W, Margreiter R, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant. 2009;9:2355–61.
46. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–67.
47. MacQuillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis. 2003;7:941–956, ix.
48. Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis. 2008;12:461–472, xi.
49. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30:1121–7.
50. Welsh FK, Wigmore SJ. Roux-en-Y Choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation. 2004;77:602–4.
51. Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003.
52. Yeoman AD, Westbrook RH, Zen Y, Bernal W, Al-Chalabi T, Wendon JA, O’Grady JG, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome. J Hepatol. 2014;61:876–82.
53. Verma S, Maheshwari A, Thuluvath P. Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology. 2009;49:1396–7.
54. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–53.
55. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372–81.
56. Heimbach JK, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant. 2013;13:363–8.
57. Lin MY, Tavakol MM, Sarin A, Amirkiai SM, Rogers SJ, Carter JT, Posselt AM. Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates. Surg Obes Relat Dis. 2013;9:653–8.
58. Lin MY, Tavakol MM, Sarin A, Amirkiai SM, Rogers SJ, Carter JT, Posselt AM. Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. Surg Endosc. 2013;27:81–5.
59. Lazzati A, Iannelli A, Schneck AS, Nelson AC, Katsahian S, Gugenheim J, Azoulay D. Bariatric surgery and liver transplantation: a systematic review a new frontier for bariatric surgery. Obes Surg. 2015;25:134–42.
60. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718–24.
61. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology. 2003;125:1733–41.
62. Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML, Fontana RJ, et al. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry. Gastroenterology. 2005;129:494–503.
63. Brandhagen DJ. Liver transplantation for hereditary hemochromatosis. Liver Transpl. 2001;7:663–72.
64. Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–111.
65. Beinhardt S, Leiss W, Stattermayer AF, Graziadei I, Zoller H, Stauber R, Maieron A, et al. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. Clin Gastroenterol Hepatol. 2014;12:683–9.
66. Catana AM, Medici V. Liver transplantation for Wilson disease. World J Hepatol. 2012;4:5–10.
67. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360:2749–57.
68. Martin P, DiMartini A, Feng S, Brown R Jr., Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65.